UNITY Biotechnology (UBX)
(Delayed Data from NSDQ)
$1.48 USD
+0.01 (0.68%)
Updated May 17, 2024 04:00 PM ET
After-Market: $1.48 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth A Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
UBX 1.48 +0.01(0.68%)
Will UBX be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for UBX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for UBX
All You Need to Know About UNITY Biotechnology (UBX) Rating Upgrade to Buy
Unity (UNX) Down on Disappointing Results From Wet AMD Study
UBX: What are Zacks experts saying now?
Zacks Private Portfolio Services
All You Need to Know About UNITY Biotechnology, Inc. (UBX) Rating Upgrade to Strong Buy
Bears are Losing Control Over UNITY Biotechnology, Inc. (UBX), Here's Why It's a 'Buy' Now
Other News for UBX
Buy Rating on Unity Biotechnology: Promising Future for UBX1325 in Diabetic Macular Edema Treatment
UNITY Biotechnology, Inc. Reports First Quarter 2024 Financial Results and Business Updates
UBX Stock Earnings: Unity Biotechnology Beats EPS for Q1 2024
Unity Biotechnology GAAP EPS of -$0.34
Unity Biotechnology reports Q1 EPS (34c), consensus (48c)